Indivior Pharmaceuticals, Inc. INDV
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Not applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on equity has no reading this year — return on capital employed, just below, still does: 77%.
The 4-year record
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue $B | 1.2 | 1.2 | 1.1 | 0.9 |
| Operating income $B | 0.3 | 0.0 | −0.2 | −0.1 |
| EBITDA $B | 0.3 | 0.1 | −0.1 | −0.1 |
| Income tax $B | 0.0 | 0.0 | −0.0 | −0.0 |
| Net income $B | 0.2 | 0.0 | −0.1 | −0.0 |
| Free cash flow $B | −0.1 | 0.0 | −0.3 | −0.0 |
| EPS, diluted $ | 1.64 | 0.05 | −0.92 | −0.32 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — |
| ROE % — not applicable: negative equity | — | — | — | — |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 4 of the 4 fiscal years we could check. 32 checks were skipped: the balance sheet is not tagged before 2023. 15 checks were skipped: EPS is not tagged before 2022. 15 checks were skipped: revenue is not tagged before 2022.